A new Lancet Psychiatry review examined 54 randomized trials of cannabinoids for mental disorders and substance use disorders, and the evidence was thinner than many public claims suggest. A few outcomes showed signals, especially in cannabis use disorder, sleep-time outcomes in insomnia, tic severity, and autism-related measures, but much of the literature remained low certainty and short-term. This physician-guided review explains what the paper actually found, what it did not test, and how to think about the gap between clinical enthusiasm and evidence quality.
[no_toc] Study Review • Psychiatry • Evidence Interpretation Cannabis Use Disorder Psychiatric Risk: What This 2026 Study Actually Shows A careful review of a large new study comparing cannabis use disorder with...
Post-Covid Baseline: 7 Hidden Aftershocks Reshaping Health
The pandemic did not end so much as it settled into us, quietly reshaping how much life our bodies can carry. The post Covid baseline explains why so many people feel more tired, more isolated, and more symptomatic, even when nothing obvious is “wrong.” This piece unpacks what changed, why seniors felt it first, and how care, including thoughtful cannabis use, can respond without pretending nothing happened.